aviscera bioscience  
AVISCERA BIOSCIENCE  
line decor
  HOME  ::  
line decor
   
 
Soluble Interleukin 6 Receptor ELISA
Soluble Glycoprotein 130 (sgp130) ELISA
In the animal model of brain metastasis using human lung squamous cell carcinoma-derived cells (HARA-B) inoculated into the left ventricle of the heart of nude mice, metastasized tumor cells and brain resident cells interact with each other. Among them, tumor cells and astrocytes have been reported to stimulate each other, releasing soluble factors from both sides, subsequently promoting tumor growth significantly. Among the receptorsfor soluble factors released from astrocytes, only IL-6 receptor (IL-6R) on tumor cells was up-regulated during the activation with astrocytes. Application of monoclonal antibody against human IL-6R (tocilizumab) to the activated HARA-B cells, the growth of HARA-B cells stimulated by the conditioned medium of HARA-B/astrocytes was significantly inhibited. Injecting tocilizumab to animal models of brain metastasis starting at three weeks of inoculation of HARA-B cells, two times a week for three weeks, significantly inhibited the size of the metastasized tumor foci. The up-regulated expression of IL-6R on metastasized lung tumor cells was also observed in the tissue from postmortem patients. These results suggest that IL-6R on metastasized lung tumor cells would be a therapeutic target to inhibit the growth of the metastasized lung tumor cells in the brain.
Noda M, et al. Int J Mol Sci. 2012 Dec 27;14(1):515-26.
Biomarkers such as interleukin-6 (IL-6), soluble interleukin-6 receptor (sIL-6R), and high sensitive C-reactive protein (hsCRP) have been reported to be elevated in acute myocardial infarction (AMI). The aim of this study is to determine the relationship between these markers during AMI, as well as their relationship to clinical parameters in an effort to discern their predictive potential in cardiac events. Serum was collected from 73 patients with; AMI, stable coronary artery disease (CAD), and controls during cardiac catheterization. Biomarker levels were determined and correlated with clinical data. IL-6 (11.75pg/ml, P<0.05) and sIL-6R (41,340pg/ml, P=0.05) were elevated in AMI compared with CAD and controls. At presentation, hsCRP was elevated in AMI patients (4.69mg/L) compared to controls (2.69mg/L, P<0.05); however, there was a significant decrease in hsCRP between AMI (4.69mg/L) and CAD patients (7.4mg/L, P<0.05). After 24h post-AMI hsCRP levels were increased compared to stable CAD (60.46mg/L, P<0.05) and were preceded by increased IL-6 at presentation. Soluble Gp130 (sGp130) showed no significant change between AMI, CAD, and control patients. However, sGp130 positively correlated with peak troponin in AMI (R=0.587, P<0.01), and negatively correlated with previous AMI (R=-0.382, P<0.05). Circulating monocyte mRNA expression isolated from selected AMI patients showed an increase in IL-6 mRNA (5.28-fold, P<0.01) and a decrease in both IL-6R (0.374-fold, P<0.01) and sGp130 mRNA (0.38-fold, P<0.01) as compared to CAD and controls. Results demonstrate that IL-6 and sIL-6R are associated with AMI and cardiac injury. These data support the hypothesis that trans-IL-6 receptor binding may alter intracellular signaling, and blocking of IL-6 receptor binding may be pathogenic in AMI. These data may be predictive of mechanism(s) by which plaques become unstable and rupture.
Anderson DR,  et al. Cytokine. 2013 Jun;62(3):395-400. d

OBJECTIVE: Increased interleukin-6 plasma levels have been reported in metabolic syndrome (MS); nevertheless, it is unclear whether interleukin-6 activity is exerted through direct signalling only or also through the "trans-signalling". This issue is important to clarify since signalling and "trans-signalling" affect different tissues. We investigated the relationship between MS and the interleukin-6 system in an older population.

METHODS: Data from 997 older community dwelling individuals (age≥65 years; females: 56.2%) enrolled the InChianti study were analysed. Interleukin-6, soluble interleukin-6 receptor (sIL-6r), and soluble glycoprotein 130 (sgp130) were measured on plasma by ELISA. MS was defined by the NCEP ATP III criteria; 309 individuals (31%) resulted affected by MS.

RESULTS: Subjects with MS had higher interleukin-6 and sgp130 levels compared to controls; a trend toward higher levels of sIL-6R was also observed. The risk of having MS was increased in individuals with high sIL-6r or/and sgp130 levels, independent of age, gender, and interleukin-6 levels. Elevated sgp130 levels were associated with higher plasma glucose, HOMA, triglycerides, and with diabetes both in subjects with and without MS. Although the risk of high sgp130 levels was generally associated with MS (O.R.: 1.77, 95%C.I.: 1.39-2.25), this excess of risk was not present in MS phenotypes excluding the criteria "elevated glucose" or "elevated triglycerides". Furthermore, the association between sgp130 and MS disappeared after adjustment for HOMA.

CONCLUSIONS: We found that older individuals with MS have increased sgp130 plasma levels compared with controls; nevertheless, our data suggest that this association might be mediated by insulin resistance.

Zuliani G, et al. Atherosclerosis. 2010 Sep 22. [Epub ahead of print]

human IL-6R ELISA Kit SK00155-08 enables to measture human samples from aviscera bioscience
Human soluble Interleukin 6 Receptor ELISA
Code No.: SK00155-08
Size: 96 T
Price: $360.00 USD
Standard Range:7.8-600 pg/ml
Dynamic Range: 7.8- 600 pg/ml
Sensitivity:3 pg/ml
Sample Type: serum, EDTA plasma
Sample requres: 5-10 ul, 100 ul per well of100-fold diluted samples.
IntraCV: 4-6%
InterCV: 8-10%
Protocol: PDF
Human soluble gp130 ELISA
Code No.: SK00155-01
Size: 96 T
Price: $360.00 USD
Standard Range:156-10000 pg/ml
Dynamic Range: 156- 10000 pg/ml
Sensitivity:78 pg/ml
Sample Type: serum, EDTA plasma
Sample requres: 5-10 ul, 100 ul per well of 50-fold diluted samples.
IntraCV: 4-6%
InterCV: 8-10%
Protocol: PDF
   
mouse IL6 Receptor elisa kit from aviscera bioscience
Mouse soluble IL-6R ELISA
Code No.: SK00155-09
Size: 96 T
Price: $420.00 USD
Standard Range:3.125-400 pg/ml
Dynamic Range:3.125-400 pg/ml
Sensitivity:3 pg/ml
Sample Type: serum, EDTA plasma
Sample requres: 5-10 ul, 100 ul per well of 50-fold diluted samples.
IntraCV: 4-6%
InterCV: 8-10%
Protocol: PDF
More IL-6 superfamily and gp130 ligaands related Proteins

 

 

Name
Code No.
Size
Price ($)
Soluble IL-6R (Human) ELISA Kit
96 T
360.00
Soluble gp130 (Human) ELISA Kit
96 T
360.00
SolubleIL-6R (Mouse) ELISA .
96 T
420.00